Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

Todd

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

AIR 340B New Report: Contract Pharmacy Growth in 340B

AIR 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper – The Impact of Growth in 340B Contract Pharmacy Arrangements – showingthat rapid contract pharmacy growth in the 340B program may not directly benefit the vulnerable patients for whom the program is intended. The paper highlights the growth of thousands of for-profit retail pharmacies – many of which are located in wealthier areas of the country. As of January 2014, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Scientific American WorldView Super Session: The Future of Global Innovation

Worldview

The sixth annual Scientific American WorldView super session packed the room late in the day as the 2014 BIO International Convention wrapped up in San Diego. International industry luminaries examined the global innovation ecosystem in a lively and candid conversation. Moderated by television and radio journalist, David Brancaccio, host of Marketplace Morning Report, the session explored key themes from Scientific American’s annual biotechnology edition, featuring the WorldView Scorecard and examined the many multicultural elements driving Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

NIH, Patients and Industry Ramp Up to AMP-lify Innovation

Kay Holcomb

Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading Biopharma Firms Mobilize to Tackle Tough Diseases – discussed the new Accelerating Medicines Partnership (AMP) program, which is aimed at transforming the current model for developing new treatments by jointly identifying and validating promising biological targets of disease. AMP is a new venture among the NIH, several non-profit organizations and 10 biopharmaceutical companies focused on Alzheimer’s disease; type 2 diabetes Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Gates Foundation Issues Biotech Call to Action

Mundel

Today, Trevor Mundel from the Bill & Melinda Gates Foundation discussed the untapped potential of biotech companies to help develop new and better drugs, vaccines, diagnostics, and delivery systems for global health solutions at the 2014 BIO International Convention. This is important because 90 percent of the global infectious disease burden is borne by those who live in developing countries, yet the foundation believes that little attention is paid to health solutions to address these Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,